ATE540579T1 - Pd-1-defiziente maus und ihre verwendung - Google Patents

Pd-1-defiziente maus und ihre verwendung

Info

Publication number
ATE540579T1
ATE540579T1 AT01996311T AT01996311T ATE540579T1 AT E540579 T1 ATE540579 T1 AT E540579T1 AT 01996311 T AT01996311 T AT 01996311T AT 01996311 T AT01996311 T AT 01996311T AT E540579 T1 ATE540579 T1 AT E540579T1
Authority
AT
Austria
Prior art keywords
mice
specifically
autoimmune disease
protein
antibody
Prior art date
Application number
AT01996311T
Other languages
English (en)
Inventor
Tasuku Honjo
Hiroyuki Nishimura
Original Assignee
Ono Pharmaceutical Co
Tasuku Honjo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co, Tasuku Honjo filed Critical Ono Pharmaceutical Co
Application granted granted Critical
Publication of ATE540579T1 publication Critical patent/ATE540579T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knockout animals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0325—Animal model for autoimmune diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0375—Animal model for cardiovascular diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Electronic Switches (AREA)
AT01996311T 2000-11-15 2001-11-14 Pd-1-defiziente maus und ihre verwendung ATE540579T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000347392 2000-11-15
PCT/JP2001/009951 WO2002039813A1 (fr) 2000-11-15 2001-11-14 Souris sans pd-1 et utilisation de celle-ci

Publications (1)

Publication Number Publication Date
ATE540579T1 true ATE540579T1 (de) 2012-01-15

Family

ID=18821130

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01996311T ATE540579T1 (de) 2000-11-15 2001-11-14 Pd-1-defiziente maus und ihre verwendung

Country Status (8)

Country Link
US (1) US7414171B2 (de)
EP (1) EP1334659B1 (de)
JP (2) JP3871326B2 (de)
KR (1) KR20030066657A (de)
AT (1) ATE540579T1 (de)
AU (1) AU2002224037A1 (de)
CA (1) CA2429042C (de)
WO (1) WO2002039813A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2729974T3 (es) 2003-01-23 2019-11-07 Ono Pharmaceutical Co Anticuerpo específico de PD-1 y CD3 humanas
ATE494549T1 (de) * 2003-04-16 2011-01-15 Ono Pharmaceutical Co Screening-verfahren für heilmittel gegen herzkrankheit und medizinische zusammensetzung zur behandlung von herzkrankheit
CN101050473B (zh) * 2007-02-09 2010-08-18 北京大学 抗细胞增殖或抗肿瘤药物的筛选试剂盒、筛选方法及用途
SI2376535T1 (sl) 2008-12-09 2017-07-31 F. Hoffmann-La Roche Ag Protitelesa anti-pd-l1 in njihova uporaba za izboljšanje funkcije celic t
RS61400B1 (sr) * 2013-05-02 2021-02-26 Anaptysbio Inc Antitela usmerena protiv programirane smrti-1 (pd-1)
JP6623353B2 (ja) 2013-09-13 2019-12-25 ベイジーン スウィッツァーランド ゲーエムベーハー 抗ｐｄ−１抗体並びにその治療及び診断のための使用
EP3049442A4 (de) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Verfahren zur behandlung von blutkrebs
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
BR112016029650A2 (pt) 2014-06-19 2017-10-24 Regeneron Pharma roedor, polipeptídeo pd-1, célula isolada ou tecido de roedor, célula-tronco embrionária de roedor, métodos de produzir um roedor, de reduzir o crescimento de tumor em um roedor, de matar células tumorais em um roedor e de avaliar as propriedades farmacocinéticas de uma droga que direciona pd-1 humano, e, modelo de tumor de roedor?
JP6526189B2 (ja) 2014-07-03 2019-06-05 ベイジーン リミテッド 抗ｐｄ−ｌ１抗体並びにその治療及び診断のための使用
BR112017001385B1 (pt) 2014-07-22 2023-12-05 Cb Therapeutics, Inc. Anticorpo isolado ou fragmento do mesmo que liga a pd-1, uso deste, composição, polinucleotídeo isolado e vetor de expressão
KR102476226B1 (ko) 2014-08-05 2022-12-12 아폴로믹스 인코포레이티드 항-pd-l1 항체
US9993551B2 (en) 2014-09-13 2018-06-12 Novartis Ag Combination therapies of EGFR inhibitors
CN109475536B (zh) 2016-07-05 2022-05-27 百济神州有限公司 用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合
AU2017313085A1 (en) 2016-08-19 2019-03-14 Beigene Switzerland Gmbh Use of a combination comprising a Btk inhibitor for treating cancers
CA3041684C (en) 2016-11-01 2023-09-26 Anaptysbio, Inc. Antibodies directed against programmed death- 1 (pd-1)
EP4219563A3 (de) 2017-01-09 2023-10-04 Tesaro, Inc. Verfahren zur behandlung von krebs mit anti-pd-1-antikörpern
CN110461847B (zh) 2017-01-25 2022-06-07 百济神州有限公司 (S)-7-(1-(丁-2-炔酰基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺的结晶形式、其制备及用途
CA3066518A1 (en) 2017-06-26 2019-01-03 Beigene, Ltd. Immunotherapy for hepatocellular carcinoma
WO2019108795A1 (en) 2017-11-29 2019-06-06 Beigene Switzerland Gmbh Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
TWI804572B (zh) 2018-02-09 2023-06-11 日商小野藥品工業股份有限公司 雙特異性抗體

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2143491C (en) * 1994-03-01 2011-02-22 Yasumasa Ishida A novel peptide related to human programmed cell death and dna encoding it

Also Published As

Publication number Publication date
JP2007023047A (ja) 2007-02-01
WO2002039813A1 (fr) 2002-05-23
US20040034881A1 (en) 2004-02-19
KR20030066657A (ko) 2003-08-09
EP1334659A4 (de) 2007-07-11
AU2002224037A1 (en) 2002-05-27
EP1334659A1 (de) 2003-08-13
CA2429042C (en) 2012-09-25
JP4018122B2 (ja) 2007-12-05
JPWO2002039813A1 (ja) 2004-03-18
EP1334659B1 (de) 2012-01-11
US7414171B2 (en) 2008-08-19
CA2429042A1 (en) 2002-05-23
JP3871326B2 (ja) 2007-01-24

Similar Documents

Publication Publication Date Title
ATE540579T1 (de) Pd-1-defiziente maus und ihre verwendung
Nezlin The immunoglobulins: structure and function
LTC0918797I2 (lt) Humanizuotas imunoglobulinas reaguojantis su alfa4beta7 integrinu
DK2573568T3 (en) Differentieringsassay
WO2004056847A3 (en) Human monoclonal antibodies to epidermal growth factor receptor (egfr)
CN106456749A (zh) 抗SIRPα抗体和双特异性巨噬细胞增强型抗体
RU2011148918A (ru) Иммуноглобулин с двумя вариабельными доменами и его применение
CO5611164A2 (es) Anticuerpos humanizados que reconocen el pepetido amiloide beta
ES2052077T3 (es) Un sistema de expresion para la produccion de anticuerpos monoclonales quimericos.
ATE342282T1 (de) Humane monoklonale antikörper gegen prostata spezifisches membranantigen
CA2497287A1 (en) Method of humanizing immune system molecules
CN102656460A (zh) 非交叉反应性抗IgG抗体
WO2003081993A3 (en) Transgenic aves producing human polyclonal antibodies
CN103068852A (zh) 抗人IgG1抗体
DE3788296D1 (de) Monoclonale Antikörper auf human-Interleukin-2-Rezeptor.
ATE460479T1 (de) Antikörper gegen ein den von-willebrand-faktor spezifisch spaltendes enzym und assay-system unter verwendung davon
Ranallo et al. Synthetic antigen-conjugated dna systems for antibody detection and characterization
ATE193326T1 (de) Monoklonalantikörper, linker- und beta- glucuronidase enthaltende fusionsproteine zur prodrug-aktivierung, ihre herstellung und verwendung
Nagata et al. Rapid grouping of monoclonal antibodies based on their topographical epitopes by a label-free competitive immunoassay
US20100009389A1 (en) Method of Making and Using Versatile Positive Controls and Antibody Detection Assays
CN1226306C (zh) 胎盘蛋白质13的抗体
Hock et al. Toxicity assessment and on‐line monitoring: immunoassays
EP0376851A2 (de) Molekular-Erkennungseinheiten
ATE498686T1 (de) Nicotin-acetylcholin rezeptoruntereinheit, deren isolierung und verwendung
Erdogan et al. Quantitative mechanistic model reveals key determinants of placental IgG transfer and informs prenatal immunization strategies